Jul 11, 2025

Conduit to advancing, protecting medical dermatology

This morning’s session highlights the impact of traditional and contemporary treatment types across the specialty.

P001 – Pipeline Therapies in Dermatology
10 a.m.–noon | Friday, July 11
Grand Ballroom D

Be sure to attend today’s session, P001 – Pipeline Therapies in Dermatology, for an in-depth look at key discoveries and innovations coming down the pike in dermatology. Session director Neal D. Bhatia, MD, FAAD, will lead a panel of experts to dissect the therapeutic approach for topicals, systemics, biologics, and devices.

“We’ll have panelists talking about what’s new in the pipeline, including research and early phase 1 and 2 trials. Then we’ll have the counterpoint of what’s already available and what’s about to be released,” said Dr. Bhatia, who is director of clinical dermatology at Therapeutics Clinical Research in San Diego.

Neal D. Bhatia, MD, FAADThe research pipeline in dermatology is both rich in potential and at risk of extinction of tradition, Dr. Bhatia said. As big pharma funds more research trials that focus on systemic and biologic treatments and start-up companies take risks with proof of concept and early-phase studies, he said the shortage of original topical therapies in development could pose a problem for how the next generation of dermatologists approaches diseases of the skin.

“It all stems from the departure of medical dermatology and how dermatologists are giving away medical dermatology. The result of that is less funding for new topical agents,” Dr. Bhatia said. “Sponsors are seeing the writing on the wall that these drugs aren’t going to get covered or supported, and relying on inefficient, generic drugs will lead to bad outcomes for patients. Dermatologists must fight for these new drugs and be advocates for pipeline research and potential novel mechanisms.”

In addition to identifying and categorizing new and potential therapeutic advances in early- to late-phase clinical research trials, presenters will discuss and evaluate the gaps, opportunities, and shifting treatment types that could affect the dermatology landscape.

The full panel of speakers includes Leon H. Kircik, MD, FAAD; Edward L. Lain, MD, FAAD; George Michael Lewitt, MD, FAAD; Andrea Tesvich Murina, MD, FAAD; Todd Schlesinger, MD, FAAD; Raja Sivamani, MD, FAAD; and Jonathan S. Weiss, MD, FAAD.